Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Mavyret
|
| gptkbp:activities |
N S3/4 A protease inhibitor
|
| gptkbp:appointed_by |
oral tablet
|
| gptkbp:approves |
gptkb:2017
gptkb:FDA |
| gptkbp:can_be_used_with |
gptkb:Pibrentasvir
|
| gptkbp:clinical_trial |
Phase 3
|
| gptkbp:contraindication |
severe liver disease
|
| gptkbp:developed_by |
gptkb:Abb_Vie
|
| https://www.w3.org/2000/01/rdf-schema#label |
Glecaprevir
|
| gptkbp:ingredients |
C20 H25 N5 O4 S
|
| gptkbp:interacts_with |
gptkb:atazanavir
gptkb:efavirenz gptkb:St._John's_Wort gptkb:carbamazepine gptkb:rifampin |
| gptkbp:is_atype_of |
J05 A E09
|
| gptkbp:is_used_for |
treatment of hepatitis C
|
| gptkbp:marketed_as |
gptkb:legislation
gptkb:Australia gptkb:United_States gptkb:Native_American_tribe |
| gptkbp:side_effect |
fatigue
headache nausea |
| gptkbp:traded_on |
gptkb:Mavyret
|
| gptkbp:type_of |
1256580-50-0
|